Last updated: May 25, 2026
Suppliers for Phenytoin Sodium (API, Finished Dosage, and Contract Manufacturing)
Executive summary: Phenytoin sodium is a long-established, off-patent small-molecule antiepileptic with wide global sourcing. Supply typically bifurcates into (1) API manufacturers for phenytoin (and phenytoin sodium where produced as a salt) and (2) finished-dose product suppliers (capsules/tablets for retail markets) plus (3) contract manufacturing organizations (CMOs) providing formulation, compression/encapsulation, and packaging under local regulatory filings. Downstream availability is driven mainly by drug master file (DMF) coverage, CEP/DMF status, and FDA/EMA market authorizations for the finished dosage form, rather than IP.
What suppliers provide phenytoin sodium API and bulk drug substances?
Direct answer (what to screen in supplier shortlists): prioritize suppliers that (a) hold an FDA Drug Master File for the relevant API, (b) supply consistent salt-form specifications for phenytoin sodium or produce phenytoin for downstream salt formation, (c) publish stability and polymorph/compositional controls, and (d) support DMF bridging into customer registrations.
API supply chain realities for phenytoin sodium
Phenytoin sodium is commonly manufactured and sold through established chemical routes and then converted into salt-formulations by finished-dose makers or specialty API sellers depending on customer capability. Supplier selection usually depends on:
- Salt-form specification: phenytoin sodium content, water content, and impurity profile.
- Regulatory documentation: FDA DMF coverage for US filings and/or EU CEP or equivalent certificates.
- Quality systems: cGMP compliance and batch traceability.
Supplier categories
- API manufacturers (phenytoin / phenytoin sodium)
- Sell API to branded and generic finished-dose companies.
- Provide DMFs, CoAs, and impurity trend data.
- Salt-form or intermediate specialists
- Supply phenytoin that is converted to sodium salt at the dosage-form site, or supply the salt directly.
- Finished-dose manufacturers
- Source API from one or more approved vendors, then file ANDAs/MAAs for tablets/capsules and distribution.
Which companies supply phenytoin sodium finished dosage forms (tablets, capsules)?
Direct answer (what this market looks like): phenytoin sodium tablets/capsules are typically supplied by established generic manufacturers with mature formulary lines. The competitive set in each market is shaped by local authorization and whether the manufacturer is positioned for US generic ANDA launches, EU national procedures, or other regional approvals.
Dosage-form supply segmentation
- Oral solid products: most commercial supply is tablets or capsules.
- Strength coverage: supply differs by market; manufacturers often carry a subset of strengths that match highest demand.
- Packaging: bottles vs unit dose; some suppliers support pharmacy distribution formats.
Contract manufacturing considerations
When outsourcing finished-dose production, buyers typically evaluate:
- Scale-up capability for oral solids
- Powder blending controls and uniformity
- Dissolution/particle-size strategy
- Packaging line suitability (serialization where required)
Who are the main global sourcing regions for phenytoin sodium?
Direct answer: sourcing clusters are concentrated in long-standing generic API hubs and oral-solid CDMO ecosystems, with strong representation from Asia and Europe-based manufacturers, and targeted Western Hemisphere packaging/labeling and finished-dose assembly for market distribution.
Key procurement signals
- DMF and regulatory readiness for US (FDA) and/or EU (EMA/national).
- Audit frequency and recent inspection outcomes for API and solid oral manufacturing sites.
- Supply continuity: ability to cover multiple compendial and customer-specific specs.
What criteria should buyers use to qualify phenytoin sodium suppliers?
Direct answer: buyers should qualify for compliance, spec control, and regulatory compatibility, not just price.
Qualification checklist
- Regulatory package
- FDA DMF letter access for the relevant API or controlled documentation pathway to support customer filings
- EU CEP or equivalent documentation when selling into Europe
- Quality system
- cGMP compliance for API and finished-dose
- validated analytical methods (HPLC/impurity profiling, assay, uniformity)
- Technical controls
- impurity profile including known degradants
- water content and stability claims for salt form
- polymorph or solid-state controls where relevant
- Operational resilience
- dual-sourcing options
- batch history and deviation reporting rates
- Commercial terms
- lead time, minimum order quantity, and change control responsiveness
How does supplier selection change if the goal is US generic ANDA supply?
Direct answer: for US market participation, the bottleneck is not only API availability. It is DMF coverage and the ability to support ANDA formulation, process validation, and comparability to the reference listed drug.
ANDA-relevant supplier touchpoints
- API support via DMF access or controlled letter route to support the customer’s quality section
- Ability to match salt specification and impurity limits used in the ANDA development package
- Supply of validated raw materials with consistent COAs and traceability
What patent status affects sourcing strategy for phenytoin sodium?
Direct answer: phenytoin sodium is not a new chemical entity and is generally treated as off-patent in most jurisdictions, shifting the risk profile toward regulatory and quality execution rather than freedom-to-operate for the chemical itself.
Practical sourcing implication
- Supply risk is dominated by regulatory chemistry controls and market authorizations, not by active substance patent barriers.
Where can supply chain disruption occur for phenytoin sodium?
Direct answer: disruption typically comes from API site capacity constraints, compliance issues (inspections), and salt/formulation line downtime rather than from raw material unavailability.
Common disruption points
- API plant maintenance cycles
- solvent or key raw input variability
- analytical method change control delays
- packaging line substitutions
How many suppliers exist for phenytoin sodium and how concentrated is the market?
Direct answer: the market is generally competitive with many qualified vendors globally, but concentration is often higher in regions where regulatory approvals are easier to maintain and in dosage strengths with steady demand.
What buyers should measure
- number of ANDA/MAH sources by dosage form and strength in the target country
- overlap in DMF ownership for the same API
- supply agreements for 6 to 18 month horizons
Key Takeaways
- Phenytoin sodium supply is a qualified, documentation-driven market: DMFs for API and validated oral-solid manufacturing for finished products are key.
- Supplier selection is less about exclusivity and more about regulatory packaging and quality execution (spec control, impurities, salt-form stability, and consistent COAs).
- Risk sits in compliance and continuity: audit outcomes, batch consistency, and packaging/line availability are the practical drivers.
- Procurement should prioritize a shortlist built around regulatory readiness (FDA DMF/letter access, EU documentation) and a proven track record for oral solid dosage form stability and dissolution performance.
FAQs
- What DMF coverage matters for phenytoin sodium API suppliers selling into the US?
- Which supplier qualifications are most important for oral-solid uniformity and dissolution for phenytoin sodium tablets or capsules?
- How do buyers verify salt-form consistency for phenytoin sodium across multiple API vendors?
- What documentation is typically required from phenytoin sodium finished-dose manufacturers for import and distribution?
- What supply contract terms reduce the risk of phenytoin sodium shortages (lead time, change control, and dual sourcing)?
References
No references were provided in the source material supplied.
